Hyurotics Raises 25 Billion Won in Series A Funding

Wearable robotics company Hyurotics is stepping up development of walking-assistance robots after securing Series A funding.

H-Medi, Hurotics' soft exosuit for medical gait rehabilitation. Hurotics

Hyurotics said on October 15 that it would receive 25 billion won in Series A funding. The round was led by Atinum Investment, bringing the company's cumulative funding to more than 33.5 billion won. Most of its existing major investors, including Stonebridge Ventures, Industrial Bank of Korea, AJU IB Investment and Wonik Investment Partners, participated in the follow-on round. New investors also joined in large numbers, including strategic investors (SIs) from the healthcare, retail and IT sectors such as Daewoong, Naver and Lotte, as well as Mirae Asset Venture Investment.

Hyurotics is a soft exosuit specialist founded in July 2022 by Lee Kiwook, a professor in the Department of Mechanical Engineering at Chung-Ang University. Lee led research on clothing-based wearable robots at Harvard University's Wyss Institute, where he took part in the U.S. Defense Advanced Research Projects Agency's (DARPA) Warrior Web project. A study on wearable robots designed to assist walking and running, on which Lee was the first author, was selected as a cover paper for the international journal Science in 2019.

The company's flagship product, H-Medi, is a medical gait rehabilitation soft exosuit certified by the Ministry of Food and Drug Safety as a Class II combination medical device. Designed to be worn like clothing, it uses cable-and-tendon drive technology that mimics muscle contraction and helps users walk by providing the necessary force through sensors. Since its commercialization in September 2025, H-Medi has been adopted by hospitals including Sinchon Severance Hospital, Chung-Ang University Hospital and Korea University Hospital. In June 2026, it was exported to the University of Illinois Chicago (UIC), where it is being used for stroke rehabilitation research and physical therapist training.

Hyurotics plans to use the funding to expand overseas regulatory approvals and distribution channels for H-Medi, and to develop and mass-produce H-Care, a robot designed to assist with everyday walking.

“Our goal is to help the recovery of movement that begins in hospitals lead to better health in everyday life,” said Hyurotics CEO Lee Kiwook. “With this investment, we will accelerate H-Medi's global expansion and the commercialization of H-Care, and combine them with physical AI to introduce wearable robots that help people look after their health in their daily lives.”

This content was produced with the assistance of AI translation services.